Ipamorelin vs Sermorelin: What Is the Difference?

Ipamorelin and sermorelin both prompt your pituitary gland to release growth hormone, but they use different signals, and neither is sold today as an FDA-approved medicine. Sermorelin copies the body’s own releasing hormone. Ipamorelin is a newer lab-made peptide that works through the ghrelin receptor, and FDA lists it among compounding ingredients that may present significant safety risks.

This article is general information, not medical advice or a dose recommendation. A physician decides whether either one is right for you.

What is the difference between ipamorelin and sermorelin?

The table comes from the National Library of Medicine’s PubChem entry for sermorelin, the 1998 paper that first described ipamorelin, an FDA notice on Geref and FDA’s compounding pages, all linked in the sections below.

What do ipamorelin and sermorelin have in common?

Both aim at the same result: more growth hormone from your own pituitary. Neither contains growth hormone. They differ in the doorway they use. Sermorelin knocks on the growth hormone-releasing hormone receptor. In the 1998 laboratory and animal work, ipamorelin released growth hormone through a different, ghrelin-type receptor.

Because both ask your own pituitary to respond rather than adding growth hormone from outside, people often compare them with growth hormone injections. That comparison does not make either one risk free, as the safety section below shows. Our peptide therapy overview explains how this family of treatments fits together.

Is ipamorelin or sermorelin FDA-approved?

Sermorelin. An FDA notice in the Federal Register records that Geref vials were approved in 1997 for children with growth failure and that the maker stopped selling it in 2008, a decision FDA said was not for safety or effectiveness reasons. What is prescribed today is compounded by a pharmacy. The full history is in Is sermorelin FDA approved?

Ipamorelin. We found no FDA-approved ipamorelin product. A search of DailyMed returned no label for ipamorelin, and ClinicalTrials.gov lists two completed phase 2 trials of ipamorelin, both for recovery after bowel surgery. FDA’s own page on bulk substances that may present significant safety risks (current as of 22 April 2026) lists ipamorelin acetate, added to category 2 for outsourcing facilities on 29 September 2023.

FDA’s position on any compounded medicine is that compounded drugs are not FDA-approved, so FDA does not check their safety, effectiveness or quality before they are sold. That applies to compounded sermorelin and compounded ipamorelin alike.

What do the human studies show?

For ipamorelin, the human evidence we found is narrow. A phase 2 trial of 117 adults tested ipamorelin given by vein twice a day for up to seven days after bowel surgery, to speed the return to eating. It was well tolerated, but there were no significant differences from placebo on the main or secondary measures. The median time to the first tolerated meal was 25.3 hours with ipamorelin and 32.6 hours with placebo, a gap that was not statistically significant.

That tells you little about injecting ipamorelin under the skin for weeks or months, which is how wellness clinics describe it. For sermorelin, the approval evidence is old and was for children. For either peptide we found no head-to-head trial: a PubMed search for both names returned six papers, all of them reviews rather than trials.

Is ipamorelin or sermorelin better?

We cannot honestly say either one is better, because no trial compares them and neither is approved for weight loss, muscle gain, anti-aging or athletic performance. What can be said is narrower. In the 1998 animal work, ipamorelin released growth hormone without raising the stress hormones ACTH and cortisol, which older peptides in the same family did raise. That is a laboratory finding in rats and pigs. It has not been shown to matter for people taking it today.

Sermorelin has a longer history behind it and a clearer regulatory story. Ipamorelin has more open questions and a specific FDA caution. Our own sermorelin guide says plainly that sermorelin is not a weight loss drug, and the same goes for ipamorelin.

What about ipamorelin with CJC-1295?

You will often see ipamorelin sold together with CJC-1295. We found no label or authoritative source that supports combining them. FDA’s page on bulk substances also describes serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and says the available clinical data are limited. Any combination is a physician’s decision, made against your bloodwork and history, not something to copy from an online forum.

What are the risks of each?

For ipamorelin, FDA’s page says compounded drugs containing it may pose a risk of immunogenicity (your immune system reacting to the peptide) for certain routes of administration, because of aggregation or impurities. It adds that ipamorelin contains unnatural amino acids, which make it harder to characterize. FDA also notes that a published study reported serious adverse events, including death, when ipamorelin was given intravenously to improve gastric motility. FDA says it has not identified safety information for certain other injectable routes and that it lacks enough information to know whether the drug would cause harm by those routes.

For sermorelin there is no current prescribing information to quote. Our sermorelin page covers who should not use it, such as people who are pregnant or breastfeeding, and why baseline bloodwork comes first. Whichever peptide is discussed, these are reasons to ask questions before starting:

• The product is compounded, so it has not been reviewed by FDA for safety, effectiveness or quality.
• Purity and sourcing vary. FDA’s concern about impurities and aggregation is about how the peptide is made.
• Long-term effects are not well studied. The ipamorelin human trials ran for days, not months.

How does this work at HCG Near Me?

Peptide therapy here is prescription only and decided after review, not picked from a menu. You complete an intake form, a physician licensed in Florida reviews your health, and baseline bloodwork comes before and during a course. Whether a physician prescribes either peptide is that physician’s decision, and the questions below are the ones worth asking.

The clinic is at 917 SW 87th Ave, Miami, FL 33174, and you can call (786) 724-1199 if you would rather talk it through before filling in the form.

What should you ask before starting either one?

• Is this product FDA-approved, or compounded? Which pharmacy makes it, and how is it tested?
• What is the evidence that it will do what I want, in people, at the route you would use?
• What bloodwork do I need first, including IGF-1 and glucose, and how often is it repeated?
• Do I have a history of cancer, pituitary problems or diabetes that you need to know about?
• What would make you stop the treatment?

Frequently asked questions

Next step

To find out whether either peptide is right for you, start the free intake form. A physician reviews it, and the team contacts you to schedule your free appointment. For more, see our sermorelin guide and our comparison of sermorelin vs tesamorelin.